Imatinib Novartis

Current Opinion in Investigational Drugs

Volumn 3, Issue 3, 2002, Pages 492-499

  Radford, Ian R ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CGS 57148; CYTARABINE; DAUNORUBICIN; ERYTHROMYCIN; HYDROXYUREA; IMATINIB; METHOTREXATE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CHRONIC MYELOID LEUKEMIA; CYTOTOXICITY; DIARRHEA; DISEASE MODEL; DOSE RESPONSE; DRUG BINDING; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG SYNTHESIS; EDEMA; GASTROINTESTINAL TUMOR; IC 50; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LEUKEMIA CELL LINE; LIVER TOXICITY; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036225236     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Preclinical evaluation of a selective inhibitor of the ABL tyrosine kinase as a therapeutic agent for chronic myelogenous leukemia
2. Tyrphostin induced growth inhibition - Correlation with effect on p210Bcr-Abl autokinase activity in K562 chronic myelogenous leukemia
3. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
4. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
5. Potent and selective inhibitors of the Abl-kinase: Phenlyamino-pyrimidine (PAP) derivatives
6. Drug development pipeline: CGP-57148
7. Novartis R&D Investor Seminar, New York
8. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)
9. Selective pharmacological inhibition of wild type and mutant C-KIT receptor tyrosine kinase activity in hematopoietic cells
10. The tyrosine kinase inhibitor STI-571 preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM
11. Novartis Oncology
12. 4 New drugs including Tamiflu, Arimidex recommended for approval
13. More than fifty abstracts on Novartis investigational leukemia agent Glivec, formerly STI-571, presented at major medical meeting
14. American Society of Hematology 42nd Annual Meeting - Overnight Report (Part IV), San Francisco, CA, USA
15. Novartis studies Glivec as first-line therapy for CML in phase III trials
16. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL+ leukemic cells to the Abl inhibitor STI571
17. A phase II study of ST1571 in adult patients with philadelphia chromosome positive chronic myeloid leukemia in accelerated phase
18. Phase II study of ST1571, a tyrosine kinase inhibitor, in patients (pts) with resistant or refactory philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML)
19. Drug Development Pipeline: Glivec
20. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-kinase/AKT pathway
21. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class
22. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
23. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth
24. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
25. Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells
26. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
27. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
28. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors
29. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571
30. Novartis ships Gleevec (imatinib mesylate) within 24 hours of FDA approval
31. Novartis Gleevec GI indication could be based on positive marker screening
32. American Society of Clinical Oncology - 37th Annual Meeting (Part IX), San Francisco, CA, USA
33. American Society of Clinical Oncology - 37th Annual Meeting (Part XI), San Francisco, CA, USA
34. Gleevec data show response rates and duration of responses increase over time
35. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers
36. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner
37. The tyrosine kinase Abl-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;12)(q25;p13): Molecular cloning of both reciprocal transcripts
38. Comparative tyrosine-kinase profiles in colorectal cancers: Enhanced arg expression in carcinoma as compared with adenoma and normal mucosa
39. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
40. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
41. STI571 revolution: Can the newer targeted drugs measure up?
42. Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement
43. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop
44. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
45. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
46. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used santileukemic agents
47. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
48. ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis
49. ARG tyrosine kinase activity is inhibited by STI571
50. BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27Kip1 expression
51. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors
52. European - Pharma & Biotech Model Book
53. Switzerland Pharmaceuticals - Novartis: Encouraging mix and momentum in H1
54. Investor relations: Presentations - Morgan Stanley Dean Witter Pan-European Healthcare Conference
55. Health Canada approves unique leukemia medication, Gleevec(x), following priority review - Breakthrough oral cancer drug, discovered and developed by Novartis, approved for chronic myeloid leukemia
56. Novartis submits supplemental NDA with US Food and Drug Administration for Gleevec (imatinib mesylate) for treatment of certain GI tumors
57. Novartis R&D Day October 30, 2001
58. Novel Novartis leukemia drug, Glivec, receives approval in Japan for CML
59. Novel Novartis leukemia drug Glivec receives approval in European Union
60. Drug development: Imatinib
61. 9 NCEs including glivec, rebetol listed
62. Early positive Glivec® data in newly diagnosed chronic myeloid leukemia (CML) study prompt major protocol changes
63. Novartis submits application to the European Union for Glivec for treatment of GI stromal tumors
64. FDA approves Novartis drug Glivec for a life-threatening GI cancer
65. Prescribing Information: Gleevec Novartis